COMPLETE LISTING OF AMENDED CLAIMS

1. (currently amended) A process for producing a taste-masked oral dosage form comprising producing active ingredient-containing shaped articles, coating the active ingredient-containing shaped articles with a film coating consisting of

   a) polyvinyl acetate,

   b) hydrophilic additives,

   c) 0 to 20% other conventional coating ingredients and

   d) ~~and~~ 0 to 30% of a physiologically tolerated acid,

   and compressing the coated shaped articles with conventional tablet excipients.

2. (previously presented) The process as claimed in claim 1, wherein the hydrophilic additives are selected from the group of film-forming water-soluble polymers and/or from the group of water-insoluble but swelling polymers and/or from the group of very fine-particle dusting agents.

3. (previously presented) The process as claimed in claim 2, wherein the film-forming water-soluble polymers are selected from the group consisting of poly(vinyllactams), vinylpyrrolidone/vinyl acetate copolymers, polyvinyl alcohols and cellulose derivatives, the water-insoluble but highly swelling polymers are selected from the group consisting of crosslinked poly(vinyllactams), cellulose or cellulose derivatives and starch derivatives and the fine-particle dusting agents are selected from the group consisting of highly disperse silicas, fine-particle starches, fine-particle celluloses and fine-particle salts of phosphoric acid.

4. (previously presented) The process as claimed in claim 1, wherein the amount of polyvinyl acetate to hydrophilic additives is between 1:0.1 and 1:0.75.

5. (canceled)

6. (previously presented) The process as claimed in claim 1, wherein the taste-masking coating comprises 5 to 25% by weight based on the total weight of the coated shaped articles.

7. (currently amended) An oral dosage form preparation comprising shaped articles with an active ingredient-containing core and a taste-masking coating consisting of

a) polyvinyl acetate,

b) hydrophilic additives,

c) other conventional coating ingredients and

d) ~~and, where appropriate~~ optionally, a physiologically tolerated acid or base,

wherein the dosage form is obtained by compression of the preparation with conventional tablet excipients.

8. (currently amended) An oral dosage form preparation as claimed in claim 7, which comprises the following substances based on the weight of the core

a) 30 to 98% active ingredient,

b) 2 to 70% binder,

c) 0.1 to 5.0% emulsifier ~~and, where appropriate~~,

d) 2 to 30% disintegrant and

e) ~~and, where appropriate,~~ 0 to 20% of a physiologically tolerated acid or base.

9. (previously presented) An oral dosage form preparation as claimed in claim 7, which comprises as active ingredients food supplements or additives, vitamins, minerals or trace elements or active pharmaceutical ingredients.

10. (previously presented) An oral dosage form preparation as claimed in claim 7, which comprises active pharmaceutical ingredients as active ingredients.

11. (previously presented) An oral dosage form preparation as claimed in claim 7, which comprises as active ingredient acetaminophen, ibuprofen, naproxen, chlorpheniramine, dextromethorphan, acetylsalicylic acid, loperamide, pseudoephedrine, diphenhydramine, famotidine, cimetidine, ranitidine, nizatidine, salts or combinations thereof.

12. (canceled)

13. (original) A taste-masked oral dosage form as claimed in claim 12, wherein from 0 to 40% of a physiologically tolerated acid or base are added to the tablet mixture.

14. (canceled)